Pharma Pioneer

MEI Pharma's Leadership Team Consolidates Approach to Progress Voruciclib and ME-344 Development

16 May 2024
2 min read

MEI Pharma's Board of Directors has made a strategic decision to focus on the clinical development of their drug candidates, voruciclib and ME-344, based on positive clinical data. The company will not be proceeding with a second capital return as outlined in their agreement with Anson Funds and Cable Car Capital, opting instead to conserve capital and extend operational runway. The decision is aimed at measured investment and prioritizing the development of a new formulation of ME-344 for a Phase 1 study, along with advancing voruciclib's clinical development. D

avid Urso, CEO of MEI Pharma, highlighted the potential of both drug candidates in treating cancer patients and emphasized the importance of a strategic approach to resource allocation. Voruciclib, an oral CDK9 inhibitor, is being developed in combination with venetoclax to treat patients with relapsed/refractory AML, while ME-344 is being investigated for its potential across various solid tumors when combined with VEGF inhibitors like Avastin

The company's strategy includes advancing voruciclib to new clinical milestones by the end of 2025 and developing a new formulation of ME-344 to enhance its therapeutic strategy. MEI Pharma has initiated research for the new ME-344 formulation, aiming to improve its biological activity and patient convenience. The company's recent clinical data for voruciclib and ME-344 have shown promising results, supporting the potential of these drugs in treating cancer. 

MEI Pharma is a clinical-stage pharmaceutical company dedicated to developing innovative cancer therapies. Their pipeline includes voruciclib and ME-344, which are being evaluated in combination with standard-of-care treatments to overcome resistance mechanisms and address significant medical needs. The company's approach involves acquiring promising cancer agents and creating value through development and strategic partnerships.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Cbio A/S, Pioneer in T-Cell Treatments, Releases 2023 Financials as It Gears Up for Clinical Trials with Secured Funding of DKK 40 Million
Pharma Pioneer
3 min read
Cbio A/S, Pioneer in T-Cell Treatments, Releases 2023 Financials as It Gears Up for Clinical Trials with Secured Funding of DKK 40 Million
16 May 2024
April 12, 2024 —Cbio A/S, a biopharmaceutical firm based in Copenhagen, has announced its financial results for 2023 and provided an update on the company's progress.
Read →
Agenus Reveals Enhanced Phase 1 Outcomes and Advances in MSS CRC Treatment with BOT/BAL Combo Therapy
Pharma Pioneer
2 min read
Agenus Reveals Enhanced Phase 1 Outcomes and Advances in MSS CRC Treatment with BOT/BAL Combo Therapy
16 May 2024
Agenus Inc. has reported new findings from its Phase 1 clinical study of BOT/BAL combination therapy for patients with metastatic colorectal cancer (CRC).
Read →
Emerging Therapies and Vaccines Tackle Aggressive Cancers at AACR
Pharma Pioneer
2 min read
Emerging Therapies and Vaccines Tackle Aggressive Cancers at AACR
16 May 2024
In a recent analysis of 7,200 cancer research abstracts from the American Association for Cancer Research's (AACR) annual gathering, several significant trends emerged.
Read →
First Patient Receives AVB-101 Gene Therapy in ASPIRE-FTD Trial for Frontotemporal Dementia Linked to GRN Gene Mutations
Pharma Pioneer
3 min read
First Patient Receives AVB-101 Gene Therapy in ASPIRE-FTD Trial for Frontotemporal Dementia Linked to GRN Gene Mutations
16 May 2024
April 15, 2024 —An innovative gene therapy named AVB-101 is currently under investigation to treat frontotemporal dementia (FTD) caused by progranulin (GRN) gene mutations.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.